AHCDO's objectives include
advancing the care and treatment of people with haemophilia in Australia; and
promoting haemophilia research and disseminating the results of such research.
Explore AHCDO research
-
AHCDO Research Fellow
AHCDO suports an early- or mid-career clinician to undertake research activities for 12 months.
-
John Lloyd Clinical Excellence Fund
The John Lloyd Cinical Excellence Fund provides funds for investigator intiated research projects focussed on bleeding disordes.
-
Research Committee
AHCDO Research Committe mets quarterly.
HTC Directors and Associate Members are welcome to join the Committee.
The Research comittee also welcomes representatives from ABDR Data Maager Group and Health Professional Group.
AHCDO Research Publications
Ramanan R, Parikh S, Aung LL, McFadyen JD, Tran HA. Intraindividual bleeding outcomes in patients with hemophilia A on emicizumab prophylaxis in Australia. Blood Vessels, Thrombosis & Hemostasis. 2024;1:100005
Ramanan R, Evans N, Kaplan Z, McFadyen JD, Tran HA. Mutational landscape, inhibitor development, and health-care burden in non-severe haemophilia a: A single-centre Australian experience. Haemophilia. 2024
Ramanan R, McFadyen JD, Perkins AC, Tran HA. Congenital fibrinogen disorders: Strengthening genotype-phenotype correlations through novel genetic diagnostic tools. Br J Haematol. 2023;203:355-368
George C, Parikh S, Carter T, Morris A, Cramey C, McElroy K, Tran H. Haemophilia joint health score (HJHS) usage, patterns and outcome data in patients with haemophilia a and haemophilia b in Australia: A descriptive study using the Australian bleeding disorders registry (ABDR). Haemophilia. 2023;29:1135-1141
George C, Parikh S, Carter T, McCosker J, Carlino S, Tran H. Evaluation of treatment and outcome for patients with haemophilia a and haemophilia b on extended half-life (EHL) factor products: A 12-month data analysis. Haemophilia. 2023;29:1283-1290
Hunt S, Robertson J, Conn J, Casey J, Royle J, Collins J, Hourigan M, Richmond J, Yang Wang T, Mills A, Mason J. A low-dose rituximab regimen for first-line treatment of acquired haemophilia A. Eur J Haematol. 2022;108:28-33
Campbell S, Mason J, Prasad R, Ambrose H, Hunt S, Tran H. Acquired haemophilia and haemostatic control with recombinant porcine factor VIII: Case series. Intern Med J. 2021;51:215-219
Brown LJ, La HA, Li J, Brunner M, Snoke M, Kerr AM. The societal burden of haemophilia A. II - the cost of moderate and severe haemophilia a in Australia. Haemophilia. 2020;26 Suppl 5:11-20
Brennan Y, Parikh S, McRae S, Tran H. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation. Haemophilia. 2020;26:529-535
Mezhov V, Campbell S, Powell A, Tran H. Pseudotumours in haemophilia: Non-adherence, under-reporting bleeds or bad luck? Intern Med J. 2019;49:1171-1173
Dunkley S, Curtin JA, Marren AJ, Heavener RP, McRae S, Curnow JL. Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy. Med J Aust. 2019;210:326-332
Campbell S, Parikh S, Tran HA. Complication rates of central venous access devices in patients with inherited bleeding disorders in Australia. Br J Haematol. 2019;186:e86-e88
Mason JA, Parikh S, Tran H, Rowell J, McRae S. Australian multicentre study of current real-world prophylaxis practice in severe and moderate haemophilia A and B. Haemophilia. 2018;24:253-260
Mason JA, Aung HT, Nandini A, Woods RG, Fairbairn DJ, Rowell JA, Young D, Susman RD, Brown SA, Hyland VJ, Robertson JD. Demonstration of a novel Xp22.2 microdeletion as the cause of familial extreme skewing of X-inactivation utilizing case-parent trio SNP microarray analysis. Mol Genet Genomic Med. 2018;6:357-369
Anderson JA, Mason JA, Halliday B. Clinical outcomes and patient satisfaction following total hip and knee arthroplasty in patients with inherited bleeding disorders: A 20-year single-surgeon cohort. Haemophilia. 2018;24:786-791
Favaloro EJ, Bonar R, Favaloro J, Koutts J. Diagnosis and management of von Willebrand disease in Australia. Semin Thromb Hemost. 2011;37:542-554
Dunkley SM, Russell SJ, Rowell JA, Barnes CD, Baker RI, Sarson MI, Street AM. A consensus statement on the management of pregnancy and delivery in women who are carriers of or have bleeding disorders. Med J Aust. 2009;191:460-463
AHCDO Conference Presentations
Ramanan R, P'Ng S, Goruppi M, Curnow J, Hooi A, Perkins AC, McFadyen JD, Tran HA. Phenotypic characterisation of congenital fibrinogen disorders in Australia. ISTH. 2024
Ramanan R, Parikh S, McFadyen JD, Tran H. Evaluation of real-world bleeding outcomes in patients with haemophilia A (HA) with or without inhibitors on emicizumab prophylaxis in Australia. ISTH. 2023
Ramanan R, P'Ng S, Goruppi M, McFadyen JD, Tran H. Evaluation of real-world peri-operative outcomes in patients with haemophilia a (ha) with or without inhibitors on emicizumab prophylaxis in Australia. Blood. 2022
Ramanan R, Parikh S, McFadyen JD, Tran H. Phenotypic characterisation of congenital fibrinogen disorders: A single centre experience. Blood. 2022
Ramanan R, Parikh S, McFadyen JD, Tran H. Evaluation of real-world bleeding outcomes in patients with haemophilia A (HA) with or without inhibitors on emicizumab prophylaxis in Australia. Blood. 2022
Ramanan R, Parikh S, McFadyen JD, Tran H. Evaluation of real-world bleeding outcomes in patients with haemophilia A (HA) with or without inhibitors on emicizumab prophylaxis in Australia. Monash University Translational Symposium. 2022
Parikh S, George C, McRae S, Carter T, McCosker J, Carlino S, Tran H. Comprehensive evaluation of treatment and outcome for patients with haemophilia a and haemophilia b on extended half-life (EHL) products: A 12-month data analysis. Blood. 2021
Tiao J, Powell S, Gilmore G, Veedu R, Wilton S, Baker RI. Targeted exon skipping as a potential gene correction therapy for haemophilia. ISTH. 2019
Tiao J. Alternative splicing as a future treatment for haemophilia A. Blood. 2019
Mason J, Parikh S, McRae S, Barnes CD. Impact of the sippet study on management of Australian pups. International Society on Thrombosis and Haemostasis. ISTH. 2019
Campbell S, Parikh S, Tran H. Genetic landscape of haemophilia A and B in Australia. ISTH. 2019
Campbell S, Ekert JE, Furmedge JF, Barnes CD. Haemostatic therapy for the insertion of central venous access devices in severe haemophilia A and B - Melbourne paediatric protocol. ISTH. 2019
Brennan Y, Parikh S, McRae S, Tran H. Extended half-life clotting factor use in Australia. Blood. 2019
Brennan Y, Kershaw G, Cai N, Curtin JA. Investigation of a prolonged APTT reveals a rare finding. Blood. 2019
Brennan Y, Hooi A, Shoemark R, Curtin JA. SMS bleed capture project. Blood. 2019
Brennan Y. The basics about blood clotting and how this interacts with factor replacement/novel therapies. 19th Australian Conference on haemophilia, VWD & rare bleeding disorders. 2019
Tiao J. Gene skipping of factor VIII gene transcript as a future treatment for haemophilia A. 10th Congress of APSTH. 2018
Tran H. Exploring the possible effects of tranexamic acid administration on the immune and inflammatory responses in patients with haemophilia. ISTH. 2017
Menezes M, Wilton S, Veedu R, Hughes QW, Baker RI. Altering the splicing of the F8 mRNA transcript as a future treatment for haemophilia. HAA Annual Scientific Meeting. 2017
Mason J, Parikh S. In pursuit of pristine joints: Where are we with prophylaxis? 18th Australian & New Zealand Conference on Haemophilia & Rare Bleeding Disorders. 2017
McCosker J. Remote control – patient and clinician satisfaction of using telehealth. World Federation of Haemophilia Congress. 2016